Effect of Different Insulin Therapies on Obstetric-Fetal Outcomes

5Citations
Citations of this article
45Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

To evaluate the effectiveness of the different insulin therapies on obstetrics-fetal outcomes in women with pregestational diabetes mellitus. We enrolled 147 pregnant women with pre-existing type 1 or 2 diabetes mellitus. Clinical and biochemical parameters were analysed in relation to obstetric and fetal outcomes. 14.2% received treatment with Neutral Protamine Hagedorn insulin and short-acting insulin analogues; 19% with premixed human insulin; 40.1% with insulin glargine and lispro, 6.2% with detemir and aspart and 20% with continuous subcutaneous insulin infusion. All 5 types of treatment achieved a reduction of the mean HbA1c during pregnancy (p = 0.01). Pre-pregnancy care was carried out for 48% of patients. We found no statistically significant differences between the different insulin therapies and the obstetric-fetal outcomes. In conclusión, the different insulin therapies used in patients with pregestational diabetes mellitus does not seem to affect obstetric-fetal outcomes.

Cite

CITATION STYLE

APA

López-Tinoco, C., Jiménez-Blázquez, J. L., Larrán-Escandón, L., Roca-Rodríguez, M. del M., Bugatto, F., & Aguilar-Diosdado, M. (2019). Effect of Different Insulin Therapies on Obstetric-Fetal Outcomes. Scientific Reports, 9(1). https://doi.org/10.1038/s41598-019-54164-4

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free